AI Prediction of Lung Function Decline: Mechanisms, Clinical Implications, and Future Directions

Abstract

Lung function decline is a pivotal factor influencing morbidity and mortality in chronic respiratory diseases. The integration of artificial intelligence (AI) algorithms into clinical practice offers unprecedented potential for predicting the trajectory of lung function with improved accuracy and granularity. This review examines the current landscape of AI-driven prediction of lung function decline, discussing epidemiological trends, mechanistic underpinnings, risk stratification, and the clinical implications of predictive modeling. Recent advances in machine learning and deep learning techniques, their validation against established guidelines, and the emerging paradigm of precision medicine are critically evaluated. We highlight the challenges, opportunities, and practical considerations for implementing AI tools in routine respiratory care, aiming to inform clinicians and healthcare professionals about the transformative potential of these technologies.

Introduction

Chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), and asthma, are associated with progressive decline in lung function, leading to increased healthcare utilization and diminished quality of life. Traditionally, lung function has been monitored using spirometry and other pulmonary function tests (PFTs), with clinical prediction models relying on demographic and clinical variables. The recent advent of AI, particularly machine learning (ML) and deep learning (DL), has enabled the analysis of vast, multidimensional datasets, offering new avenues for predicting lung function decline with greater precision. This review synthesizes recent evidence on AI-driven prediction models, their underlying mechanisms, and their clinical relevance.

Epidemiology / Disease Burden

Respiratory diseases remain among the leading causes of global morbidity and mortality. The World Health Organization estimates that COPD alone accounts for over three million deaths annually, with many more affected by asthma and various forms of ILD. Lung function decline, as measured by reductions in forced expiratory volume in one second (FEV1) or forced vital capacity (FVC), directly correlates with adverse outcomes, including exacerbations, hospitalizations, and death. The burden is exacerbated by late diagnosis and the heterogeneity of disease progression, underscoring the need for robust predictive tools that can identify at-risk individuals early and guide targeted interventions.

Pathophysiology

Lung function decline results from complex interactions between genetic predisposition, environmental exposures, and inflammatory processes. In COPD, chronic exposure to noxious stimuli, such as cigarette smoke or air pollution, leads to airway remodeling, alveolar destruction, and progressive airflow limitation. In ILD, aberrant wound healing and fibrosis impair gas exchange. The rate of decline varies markedly across individuals, influenced by factors including comorbidities, exacerbations, and therapeutic interventions. AI algorithms, trained on large-scale longitudinal datasets, can model these nonlinear and multifactorial processes, capturing subtle patterns that may escape traditional statistical approaches.

Risk Factors

Key risk factors for accelerated lung function decline include age, smoking status, occupational exposures, recurrent respiratory infections, genetic variants (such as alpha-1 antitrypsin deficiency), and poor treatment adherence. Comorbid conditions, including cardiovascular disease, diabetes, and gastroesophageal reflux disease, also contribute to worsened trajectories. AI-based models can integrate these diverse variables—both structured (e.g., laboratory results, medication history) and unstructured (e.g., clinical notes, imaging data)—to refine risk stratification and personalize prognostication.

Clinical Features

Patients with declining lung function may present with progressive dyspnea, chronic cough, wheezing, and reduced exercise tolerance. Exacerbations, characterized by worsening symptoms, accelerate functional deterioration and often prompt emergency interventions. Subclinical decline may precede overt symptoms, highlighting the importance of sensitive predictive models. AI systems can identify at-risk patients before clinical deterioration, enabling preemptive management and potentially modifying disease course.

Diagnosis

The gold standard for assessing lung function remains spirometry, with serial measurements of FEV1 and FVC providing objective markers of decline. Advanced testing, such as diffusion capacity for carbon monoxide (DLCO) and body plethysmography, offers further granularity. AI algorithms can analyze longitudinal PFT data, integrating information from electronic health records (EHRs), radiologic imaging, and molecular biomarkers to forecast individual trajectories. Recent studies have demonstrated the superior predictive accuracy of ML models compared to traditional regression-based approaches, particularly when handling large, complex datasets with missing or heterogeneous data.

Treatment & Management

Management strategies for patients at risk of rapid lung function decline focus on risk factor modification (e.g., smoking cessation, vaccination), pharmacologic therapy (bronchodilators, inhaled corticosteroids, antifibrotics), and pulmonary rehabilitation. Early identification of high-risk individuals enables timely intervention, potentially slowing disease progression. AI-driven prediction models can inform clinical decision-making, supporting tailored treatment plans and optimizing resource allocation. Integration of these tools into clinical workflows is facilitated by user-friendly interfaces and real-time decision support systems.

Recent Advances / Emerging Therapies

AI research in pulmonology has rapidly evolved, with ML and DL models trained on multi-omic and multimodal datasets showing promise in forecasting lung function decline. Convolutional neural networks (CNNs) have been applied to radiologic imaging, such as chest CT scans, to quantify emphysema and fibrosis burden, while recurrent neural networks (RNNs) excel in analyzing longitudinal clinical data. Federated learning approaches allow collaborative model training across institutions without compromising patient privacy. Moreover, explainable AI techniques enhance transparency, enabling clinicians to interpret model predictions and build trust in algorithmic recommendations. Ongoing trials are evaluating AI-guided intervention strategies to improve clinical outcomes.

Guideline Recommendations

International guidelines increasingly recognize the potential of AI in respiratory medicine. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) and American Thoracic Society (ATS) endorse the use of advanced analytics for risk stratification, provided that models are externally validated and integrated with clinical judgment. Regulatory agencies emphasize the importance of model transparency, bias mitigation, and continuous performance monitoring. Future guideline updates are expected to incorporate evidence from ongoing prospective studies, further establishing the role of AI in routine clinical care.

Conclusion

AI-driven prediction of lung function decline represents a paradigm shift in respiratory medicine, offering opportunities for earlier identification of at-risk individuals, personalized management, and improved patient outcomes. While substantial progress has been made, challenges remain regarding data quality, model interpretability, and integration into clinical workflows. Continued collaboration between clinicians, data scientists, and regulatory bodies will be essential to realize the full potential of AI in predicting and mitigating lung function decline, ultimately advancing precision respiratory care.